pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets

Journal of Controlled Release

Volumn 67, Issue 1, 2000, Pages 101-110

  Streubel, A ^a   Siepmann, J ^a   Dashevsky, A ^a   Bodmeier, R ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Controlled release; Ethylcellulose; HPMC; pH independence; Weakly basic drug

Indexed keywords

ADIPIC ACID; ETHYL CELLULOSE; FLOWLAC; FUMARIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; LACTOSE; MAGNESIUM STEARATE; SORBIC ACID; SUCCINIC ACID; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; DISSOLUTION; DRUG RELEASE; IN VITRO STUDY; MATRIX TABLET; PARTICLE SIZE; PH; PRIORITY JOURNAL; ULTRAVIOLET SPECTROPHOTOMETRY;

CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; METHYLCELLULOSE; SOLUBILITY; TABLETS; VERAPAMIL; WATER;

EID: 0034660109     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(00)00200-5     Document Type: Article

References (19)

1. Timmins P., Delargy A.M., Howard J.R. Optimization and characterization of a pH-independent extended-release hydrophilic matrix tablet. Pharm. Dev. Technol. 2:(1):1997;25-31.
2. P.L. Oren, W.M.K. Seidler, Sustained release matrix, US Patent 4,968,508, November 6, 1990.
3. R.J. MacRae, J.S. Smith, Pharmaceutical formulations, WO Patent 97/18814, May 29, 1997.
4. J.R. Howard and P. Timmins, Controlled release formulation, US Patent 4,792,452, December 20, 1988.
5. Gabr K.E. Effect of organic acids on the release patterns of weakly basic drugs from inert sustained release matrix tablets. Eur. J. Pharm. Biopharm. 38:(6):1992;199-202.
6. Thoma K., Zimmer T. Retardation of weakly basic drugs with diffusion tablets. Int. J. Pharm. 58:1990;197-202.
7. Thoma K., Ziegler I. The pH-independent release of fenoldopam from pellets with insoluble film coats. Eur. J. Pharm. Biopharm. 46:1998;105-113.
8. Thoma K., Zimmer Th. Retardation of weak basic drugs. 1. Improvement of availability problems with noscapine in diffusion pellets. Pharm. Ind. 51:(1):1989;98-101.
9. Thoma K., Zimmer Th. Retardation of weak basic drugs. 2. Optimization of availability with papaverine and codeine in diffusion pellets. Pharm. Ind. 51:(5):1989;540-543.
10. Thoma K., Knott F. Retardation of weakly basic drugs. 5. Improvement in the release of dihydroergotamine methane sulfonate from diffusion dosage forms. Pharm. Ind. 53:(7):1991;686-690.
11. Lin S.Y., Lin K.H. Water uptake and drug release behaviour of drug-loaded compacts prepared from different grades of ethylcellulose. Eur. J. Pharm. Biopharm. 42:(3):1996;193-198.
12. Higuchi W.I. Diffusional models useful in biopharmaceutics - Drug release rate processes. J. Pharm. Sci. 56:(3):1967;315-324.
13. Siepmann J., Lecomte F., Bodmeier R. Diffusion-controlled drug delivery systems: calculation of the required composition to achieve desired release profiles. J. Control. Release. 60:(2-3):1999;379-389.
14. Baker R. Diffusion-controlled systems. Baker R. Controlled Release of Biologically Active Agents. 1987;39-83 Wiley, New York.
15. Bamba M., Puisieux F., Marty J.P., Carstensen J.T. Release mechanisms in gel forming sustained release preparations. Int. J. Pharm. 2:(6):1979;307-315.
16. Siepmann J., Podual K., Sriwongjanya M., Peppas N.A., Bodmeier R. A new model describing the swelling and drug release kinetics from hydroxypropyl methylcellulose tablets. J. Pharm. Sci. 88:1999;65-72.
17. Siepmann J., Kranz H., Bodmeier R., Peppas N.A. HPMC matrices for controlled drug delivery: A new model combining diffusion, swelling and dissolution mechanisms and predicting the release kinetics. Pharm. Res. 16:1999;48-56.
18. Fan L.T., Singh S.K. Diffusion-controlled release. Fan L.T., Singh S.K. Controlled Release: A Quantitative Treatment. 1989;9-88 Springer, Berlin.
19. The Merck Index. Vol. XII:1996;Merck & Co., Inc, Whitehouse Station, NJ.